Literature DB >> 35387874

Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate.

Dusan Harmacek1, Menno Pruijm1, Michel Burnier2, Marie-Eve Muller2, Arlène Ghajarzadeh-Wurzner2, Olivier Bonny1,2,3, Anne Zanchi4.   

Abstract

Clinical Trial registry name and registration number: Empagliflozin and Renal Oxygenation in Healthy Volunteers (EMPA-REIN), NCT03093103.
Copyright © 2022 by the American Society of Nephrology.

Entities:  

Keywords:  SGLT2; empagliflozin; healthy volunteers; kidney stones

Mesh：

Substances：

Year:  2022        PMID： 35387874      PMCID： PMC9161803          DOI： 10.1681/ASN.2021111515

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   14.978


  7 in total

1.  Dual roles of brushite crystals in calcium oxalate crystallization provide physicochemical mechanisms underlying renal stone formation.

Authors:  R Tang; G H Nancollas; J L Giocondi; J R Hoyer; C A Orme
Journal:  Kidney Int       Date:  2006-04-26       Impact factor: 10.612

2.  EQUIL2: a BASIC computer program for the calculation of urinary saturation.

Authors:  P G Werness; C M Brown; L H Smith; B Finlayson
Journal:  J Urol       Date:  1985-12       Impact factor: 7.450

3.  A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.

Authors:  Akira Onishi; Yiling Fu; Rohit Patel; Manjula Darshi; Maria Crespo-Masip; Winnie Huang; Panai Song; Brent Freeman; Young Chul Kim; Manoocher Soleimani; Kumar Sharma; Scott Culver Thomson; Volker Vallon
Journal:  Am J Physiol Renal Physiol       Date:  2020-09-07

4.  SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.

Authors:  Erik J M van Bommel; Frank Geurts; Marcel H A Muskiet; Adrian Post; Stephan J L Bakker; A H Jan Danser; Daan J Touw; Miranda van Berkel; Mark H H Kramer; Max Nieuwdorp; Ele Ferrannini; Jaap A Joles; Ewout J Hoorn; Daniël H van Raalte
Journal:  Clin Sci (Lond)       Date:  2020-12-11       Impact factor: 6.124

5.  Alterations in circadian rhythmicity in calcium oxalate renal stone formers.

Authors:  Y Touitou; C Touitou; G Charransol; A Reinberg; J Thomas; A Bogdan; C Barthelemy; P Desgrez
Journal:  Int J Chronobiol       Date:  1983

6.  Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis.

Authors:  Kasper B Kristensen; Daniel P Henriksen; Jesper Hallas; Anton Pottegård; Lars C Lund
Journal:  Diabetologia       Date:  2021-03-13       Impact factor: 10.122

7.  Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.

Authors:  Anne Zanchi; Michel Burnier; Marie-Eve Muller; Arlène Ghajarzadeh-Wurzner; Marc Maillard; Nicolas Loncle; Bastien Milani; Nathalie Dufour; Olivier Bonny; Menno Pruijm
Journal:  J Am Heart Assoc       Date:  2020-06-20       Impact factor: 5.501
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.